{"organizations": [], "uuid": "daff84e87edcf8eb29de6461582d7324c0d181be", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-transgene-announces-dosing-of-firs/brief-transgene-announces-dosing-of-first-patient-in-phase-2-trial-of-tg4010-evaluation-idUSFWN1PB18S", "country": "US", "domain_rank": 408, "title": "BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.153, "site_type": "news", "published": "2018-01-17T01:01:00.000+02:00", "replies_count": 0, "uuid": "daff84e87edcf8eb29de6461582d7324c0d181be"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-transgene-announces-dosing-of-firs/brief-transgene-announces-dosing-of-first-patient-in-phase-2-trial-of-tg4010-evaluation-idUSFWN1PB18S", "ord_in_thread": 0, "title": "BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​", "locations": [], "entities": {"persons": [], "locations": [{"name": "usa", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Transgene Sa:\n* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE‘S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​\n* ‍FIRST RESULTS EXPECTED IN H2 2018​ * ‍THIS MULTI-CENTER SINGLE-ARM TRIAL WILL ENROLL UP TO 39 PATIENTS BOTH IN USA AND EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T01:01:00.000+02:00", "crawled": "2018-01-17T20:09:24.001+02:00", "highlightTitle": ""}